Companies › SystImmune
3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 3; Oncology; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Trastuzumab Receptor protein-tyrosine kinase erbB-2 inhibitor | ERBB2 | Phase 3 | Urothelial Cancer | Dec 2028 |
| BL-M05D1 | – | Phase 1 | Gastric Adenocarcinoma | Feb 2027 |
| BL-M14D1 | – | Phase 1 | Small Cell Lung Cancer Metastatic or Locally Advanced | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07021066 | BL-M05D1 | Phase 1 | Gastric Adenocarcinoma | Oncology | Feb 2027 |
| NCT07080242 | BL-M14D1 | Phase 1 | Small Cell Lung Cancer Metastatic or Locally Advanced | Oncology | Dec 2027 |
| NCT07869836 | Trastuzumab | Phase 3 | Urothelial Cancer | Oncology | Dec 2028 |
DualityBio Aston Sci. Chengdu SciMount Pharmatech Shanghai Miracogen Nuvalent
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.